NCT05333328View on ClinicalTrials.gov

OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

PHASE4RecruitingINTERVENTIONAL
Enrollment

418

Participants

Timeline

Start Date

February 6, 2023

Primary Completion Date

January 31, 2031

Study Completion Date

January 31, 2033

Conditions
Breast CancerEstrogen Receptor Positive TumorHER2-negative Breast CancerPremenopausal Breast CancerNode-positive Breast Cancer
Interventions
DRUG

Ovarian function suppression with endocrine treatments

"* Ovarian function suppression (OFS) with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.~* Either goserelin acetate or leuprorelin Acetate is allowed.~* These patients are able to choose bilateral salpingo-oophorectomy instead of OFS.~* Chemotherapy is omitted in these patients."

Trial Locations (2)

06229

RECRUITING

Gangnam Severance Hospital, Seoul

Unknown

NOT_YET_RECRUITING

Seoul National University Hospital, Seoul

All Listed Sponsors
collaborator

Seoul National University

OTHER

lead

Gangnam Severance Hospital

OTHER